These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28912902)

  • 1. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
    Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
    Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
    Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial.
    Seino H
    Diabetes Ther; 2021 Mar; 12(3):863-877. PubMed ID: 33594581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.
    Seko Y; Nishikawa T; Umemura A; Yamaguchi K; Moriguchi M; Yasui K; Kimura M; Iijima H; Hashimoto T; Sumida Y; Okanoue T; Itoh Y
    Diabetes Metab Syndr Obes; 2018; 11():835-843. PubMed ID: 30568471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
    Tobita H; Yazaki T; Kataoka M; Kotani S; Oka A; Mishiro T; Oshima N; Kawashima K; Ishimura N; Naora K; Sato S; Ishihara S
    J Clin Biochem Nutr; 2021 Mar; 68(2):173-180. PubMed ID: 33879970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice.
    Qiao P; Jia Y; Ma A; He J; Shao C; Li X; Wang S; Yang B; Zhou H
    Front Pharmacol; 2022; 13():934136. PubMed ID: 36059948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study.
    Miyake T; Yoshida O; Matsuura B; Furukawa S; Hirooka M; Abe M; Tokumoto Y; Koizumi Y; Watanabe T; Takeshita E; Sunago K; Yukimoto A; Watanabe K; Miyazaki M; Kanzaki S; Nakaguchi H; Koizumu M; Yamamoto Y; Kumagi T; Hiasa Y
    Diabetes Ther; 2022 May; 13(5):1083-1096. PubMed ID: 35312970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Intern Med; 2024 Feb; ():. PubMed ID: 38346734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery.
    Seki Y; Kakizaki S; Horiguchi N; Hashizume H; Tojima H; Yamazaki Y; Sato K; Kusano M; Yamada M; Kasama K
    J Gastroenterol; 2016 Mar; 51(3):281-9. PubMed ID: 26314837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
    Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
    Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
    Yoneda M; Iwasaki T; Fujita K; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Wada K; Saito S; Terauchi Y; Nakajima A
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S15-21. PubMed ID: 17331160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
    Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
    PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus.
    Lee CH; Wu MZ; Lui DT; Chan DS; Fong CH; Shiu SW; Wong Y; Lee AC; Lam JK; Woo YC; Lam KS; Yiu KK; Tan KC
    Diabetes Metab J; 2022 Nov; 46(6):843-854. PubMed ID: 35483674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India.
    Ghosh A; Dutta K; Bhatt SP; Gupta R; Tyagi K; Ansari IA; Venugopal VK; Mahajan H; Pandey RM; Pandey S; Misra A
    J Clin Endocrinol Metab; 2022 May; 107(6):e2267-e2275. PubMed ID: 35263436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin in patients with type 2 diabetes mellitus.
    Filippatos TD; Liberopoulos EN; Elisaf MS
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.
    Bazerbachi F; Vargas EJ; Rizk M; Maselli DB; Mounajjed T; Venkatesh SK; Watt KD; Port JD; Basu R; Acosta A; Hanouneh I; Gara N; Shah M; Mundi M; Clark M; Grothe K; Storm AC; Levy MJ; Abu Dayyeh BK
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):146-154.e4. PubMed ID: 32360804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.
    Qiang S; Nakatsu Y; Seno Y; Fujishiro M; Sakoda H; Kushiyama A; Mori K; Matsunaga Y; Yamamotoya T; Kamata H; Asano T
    Diabetol Metab Syndr; 2015; 7():104. PubMed ID: 26594248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.